D. R. Jakas

发表

Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist.

K. Ward, B. R. Smith, R. Keenan, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity.

J. Boehm, S. Hecht, R. Johnson, 1991, Journal of medicinal chemistry.

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.

Xiayang Qiu, David J Payne, M. Head, 2003, Journal of medicinal chemistry.

Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.

K. Erhard, R. Keenan, M. Lark, 1999, Bioorganic & medicinal chemistry letters.

In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4 receptor antagonist with anti-inflammatory activity.

H. Sarau, J. Foley, S. Van Horn, 1999, Prostaglandins, leukotrienes, and essential fatty acids.

Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (αvβ3) antagonist with efficacy in a restenosis model

B. Smith, T. Yue, E. Ohlstein, 1998 .

Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (αvβ3) antagonists

B. Smith, R. Calvo, R. Keenan, 1998 .

Trisubstituted pyridine leukotriene B4 receptor antagonists: synthesis and structure-activity relationships.

H. Sarau, J. Foley, D. R. Jakas, 1993, Journal of medicinal chemistry.

Orally active 7-phenylglycyl cephalosporins. Structure-activity studies related to cefatrizine (SK&F 60771).

J. R. Hoover, D. R. Jakas, L. Davis, 1976, The Journal of antibiotics.

Defining and Combating the Mechanisms of Triclosan Resistance in Clinical Isolates of Staphylococcus aureus

M. Head, N. Wallis, D. Payne, 2002, Antimicrobial Agents and Chemotherapy.

Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonists.

R. Calvo, R. Keenan, M. Parker, 1999, Journal of medicinal chemistry.

Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists.

C. E. Peishoff, K. Erhard, R. Calvo, 1996, Journal of medicinal chemistry.

Structure-activity relationships in 3-oxo-1,4-benzodiazepine-2-acetic acid GPIIb/IIIa antagonists. The 2-benzazepine series

R. Calvo, R. Keenan, C. Yuan, 1996 .

Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity

J. Boehm, R. Hertzberg, S. Hecht, 1991 .

Semisynthetic cephalosporins. Synthesis and structure-activity relationships of 7-mandelamido-3-cephem-4-carboxylic acids.

J. R. Hoover, D. R. Jakas, L. Phillips, 1974, Journal of medicinal chemistry.

Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity.

R. Hertzberg, J. Bartus, M. Mattern, 1989, Journal of medicinal chemistry.

Reaction of 2-aminobenzimidazole with bifunetional carboxylie acid derivatives. Formation of pyrimido[1,2-a] benzimidazolones†

N. M. Hall, J. R. Hoover, D. R. Jakas, 1973 .

Preparation of some trimethylpentacyclo-[5.4.0.02,6.03,10.05,9]undecane-8,11-dione derivatives

J. R. Hoover, D. R. Jakas, A. W. Chow, 1971 .

(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid: a novel high-affinity leukotriene B4 receptor antagonist.

H. Sarau, J. Foley, D. R. Jakas, 1993, Journal of Medicinal Chemistry.

Synthesis of tritiated (S)‐10‐bromoacetamidomethylcamptothecin

A. Shu, D. R. Jakas, J. Heys, 1990 .